Table 1.
Patient characteristics according to CBF subtype
| CBF-AML | AML with inv(16) | AML with t(8;21) | P value | |
|---|---|---|---|---|
| Patients, n | 215 | 109 | 106 | |
| Median age, y (range) | 32 (1-60) | 37 (1-60) | 25 (2-59) | .004* |
| Median WBC, ×109/L (range) | 18.4 (1-232) | 34.4 (1-232) | 11.5 (1.3-163) | <.001* |
| Gender (male/female) | 119/96 | 61/48 | 58/48 | .891 |
| Trial (CBF2006/ELAM02) | 142/73 | 79/30 | 63/43 | .046* |
| Outcome | ||||
| Deaths, n (%) | 35 (16) | 15 (14) | 20 (18) | .358 |
| Relapses, n (%) | 70 (33) | 34 (31) | 36 (33) | .771 |
| Number of mutations per patient | 2 (0-6) | 1 (0-5) | 2 (0-6) | .277 |
| Gene mutations | ||||
| Tyrosine kinase pathway, n (%) | 156 (73) | 87 (80) | 69 (65) | .021* |
| KIT exon 8, n (%) | 37 (17) | 22 (20) | 15 (14) | .352 |
| KIT exon 17, n (%) | 42 (20) | 16 (15) | 26 (25) | .080 |
| Codon D816 (exon 17), n (%) | 30 (14) | 13 (12) | 17 (16) | .421 |
| Codon N822 (exon 17), n (%) | 12 (6) | 2 (2) | 10 (9) | .032* |
| KIT exon 11, nm(%) | 2 (1) | 1 (1) | 1 (1) | 1.000 |
| KIT all, n (%) | 78 (36) | 36 (33) | 42 (40) | .325 |
| FLT3-TKD, n (%) | 28 (13) | 24 (22) | 4 (4) | <.001* |
| FLT3-ITD, n (%) | 14 (7) | 3 (3) | 11 (10) | .028* |
| FLT3 all, n (%) | 41 (19) | 26 (24) | 15 (14) | .083 |
| RTK (KIT and/or FLT3), n (%) | 105 (49) | 53 (49) | 52 (49) | 1.000 |
| NRAS, n (%) | 66 (31) | 42 (39) | 24 (23) | .012* |
| Codon G12, n (%) | 24 (11) | 14 (13) | 10 (9) | .518 |
| Codon G13, n (%) | 19 (9) | 9 (8) | 10 (9) | .813 |
| Codon Q61, n (%) | 34 (16) | 26 (24) | 8 (8) | .001* |
| KRAS, n (%) | 36 (17) | 29 (27) | 7 (7) | <.001* |
| Codon G12, n (%) | 15 (7) | 14 (13) | 1 (1) | <.001* |
| Codon G13, n (%) | 13 (6) | 8 (7) | 5 (5) | .569 |
| Codon Q61, n (%) | 6 (3) | 5 (5) | 1 (1) | .212 |
| RAS (NRAS and/or KRAS), n (%) | 87 (40) | 59 (54) | 28 (26) | <.001* |
| JAK2, n (%) | 3 (1) | 0 (0) | 3 (3) | .118 |
| PTPN11, n (%) | 8 (4) | 5 (5) | 3 (3) | .722 |
| CBL, n (%) | 2 (1) | 0 (0) | 2 (2) | .242 |
| Chromatin modifiers, n (%) | 51 (24) | 6 (6) | 45 (42) | <.001* |
| ASXL1, n (%) | 11 (5) | 0 (0) | 11 (10) | <.001* |
| ASXL2, n (%) | 23 (11) | 0 (0) | 23 (22) | <.001* |
| ASXL (ASXL1 or ASXL2), n (%) | 34 (16) | 0 (0) | 34 (32) | <.001* |
| KDM6A, n (%) | 9 (4) | 3 (3) | 6 (6) | .328 |
| EZH2, n (%) | 7 (3) | 0 (0) | 7 (7) | .006* |
| BCOR, n (%) | 2 (1) | 1 (1) | 1 (1) | 1.000 |
| BCORL1, n (%) | 6 (3) | 3 (3) | 3 (3) | 1.000 |
| DNA methylation, n (%) | 10 (5) | 2 (2) | 8 (8) | .057 |
| TET2, n (%) | 5 (2) | 0 (0) | 5 (5) | .028* |
| IDH1, n (%) | 3 (1) | 2 (2) | 1 (1) | 1.000 |
| IDH2, n (%) | 2 (1) | 0 (0) | 2 (2) | .242 |
| Cohesin, n (%) | 19 (9) | 0 (0) | 19 (18) | <.001* |
| RAD21, n (%) | 8 (4) | 0 (0) | 8 (8) | .003* |
| SMC1A, n (%) | 5 (2) | 0 (0) | 5 (5) | .028* |
| SMC3, n (%) | 5 (2) | 0 (0) | 5 (5) | .028* |
| STAG2, n (%) | 1 (0) | 0 (0) | 1 (1) | .493 |
| Transcription factors, n (%) | 6 (3) | 1 (1) | 5 (5) | .116 |
| ETV6, n (%) | 2 (1) | 1 (1) | 1 (1) | 1.000 |
| RUNX1, n (%) | 1 (0) | 0 (0) | 1 (1) | .493 |
| GATA2, n (%) | 2 (1) | 0 (0) | 2 (2) | .242 |
| IKZF1, n (%) | 1 (0) | 0 (0) | 1 (1) | .493 |
| Spliceosome, n (%) | 2 (1) | 1 (1) | 1 (1) | 1.000 |
| SRSF2, n (%) | 2 (1) | 1 (1) | 1 (1) | 1.000 |
| Tumor suppressors, n (%) | 11 (5) | 7 (6) | 4 (4) | .538 |
| PHF6, n (%) | 1 (0) | 0 (0) | 1 (1) | .493 |
| WT1, n (%) | 11 (5) | 7 (6) | 4 (4) | .538 |
| Additional cytogenetic abnormalities | ||||
| Loss X or Y, n (%) | 54 (25) | 0 (0) | 54 (51) | <.001* |
| Del(9q), n (%) | 16 (7) | 0 (0) | 16 (15) | <.001* |
| Del(7q), n (%) | 21 (10) | 11 (10) | 10 (9) | 1.000 |
| Trisomy 8, n (%) | 18 (8) | 12 (11) | 6 (6) | .218 |
| Trisomy 22, n (%) | 12 (6) | 12 (11) | 0 (0) | <.001* |
Adult and pediatric patients are reported together.
*
P < .05.